2Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzhe- imer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry ,2010,67:505-512.
3Alkhenizan AH, Alswes MA. The role of renin blockers in the pre- vention of diabetes. Saudi Med J,2007,28:91-95.
4Hutchinson DS, Summers R J, Bengtsson T. Regulation of AMP- activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol Ther,2008 ,119 :291-310.
5Kimura R, Okouchi M, Fujioka H, et al. Glucagon-like peptide-1 ( GLP-I ) protects against methylglyoxal-induced PC12 cell apop- tosis through the PI3K/Akt/mTOR/GCLc/redox signaling path- way. Neuroscience ,2009,162 : 1212-1219.
6Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American Col- lege of Endocrinology consensus panel on type 2 diabetes melli- tus:an algorithm for glycemic control. Endocr Pract, 2009,15: 540-559.
7Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy:a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care,2009,32 : 193-203.
8Rossi MC, Nicolucci A. Liraglutide in type 2 diabetes : from phar- macological development to clinical practice. Acta Biomed ,2009, 80:93-101.
9Wang XH, Li L, Hslscher C, et al. Val8-glucagon-like peptide-1 protects against AI31-40-induced impairment of hippocampal late- phase long-term potentiation and spatial learning in rats. Neuroscience,2010,170:1239-1248.
10Serbedzija P, Madl JE, Ishii DN. Insulin and IGF-1 prevent brain atrophy and DNA loss in diabetes. Brain Res, 2009, 1303: 179-194.
